Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 17;8(9):e70004.
doi: 10.1002/hem3.70004. eCollection 2024 Sep.

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

Thomas Chatzikonstantinou  1 , Lydia Scarfò  2   3 , Eva Minga  1 , Georgios Karakatsoulis  1 , Dimitra Chamou  1 , Jana Kotaskova  4   5 , Gloria Iacoboni  6 , Christos Demosthenous  7 , Elisa Albi  2 , Miguel Alcoceba  8 , Salem Al-Shemari  9 , Thérèse Aurran-Schleinitz  10 , Francesca Bacchiarri  11 , Sofia Chatzileontiadou  12 , Rosa Collado  13 , Zadie Davis  14 , Marcos Daniel de Deus Santos  15 , Maria Dimou  16 , Elena Dmitrieva  17 , David Donaldson  18 , Gimena Dos Santos  19 , Barbara Dreta  20 , Maria Efstathopoulou  21 , Shaimaa El-Ashwah  22 , Alicia Enrico  23 , Andrzej Frygier  24 , Sara Galimberti  25 , Andrea Galitzia  26 , Eva Gimeno  27 , Valerio Guarente  28 , Romain Guieze  29 , Sean Harrop  30 , Eleftheria Hatzimichael  31 , Yair Herishanu  32 , José-Ángel Hernández-Rivas  33 , Ozren Jaksic  34 , Elżbieta Kalicińska  35 , Kamel Laribi  36 , Volkan Karakus  37 , Arnon P Kater  38 , Bonnie Kho  39 , Maria Kislova  17 , Εliana Konstantinou  40 , Maya Koren-Michowitz  41   42 , Ioannis Kotsianidis  43 , Zuzana Kubova  44 , Jorge Labrador  45 , Deepesh Lad  46 , Luca Laurenti  47   48 , Thomas Longval  49 , Alberto Lopez-Garcia  50 , Juan Marquet  51 , Stanislava Maslejova  5 , Carlota Mayor-Bastida  52 , Biljana Mihaljevic  53   54 , Ivana Milosevic  55 , Fatima Miras  56 , Riccardo Moia  57 , Marta Morawska  58   59 , Uttam K Nath  60 , Almudena Navarro-Bailón  8 , Jacopo Olivieri  61 , Irina Panovska-Stavridis  62 , Maria Papaioannou  12 , Cheyenne Pierie  38 , Anna Puiggros  63 , Gianluigi Reda  64 , Gian M Rigolin  65 , Rosa Ruchlemer  66 , Mattia Schipani  57 , Annett Schiwitza  67 , Yandong Shen  68 , Tereza Shokralla  69 , Martin Simkovic  70 , Svetlana Smirnova  71 , Dina S A Soliman  72 , Stephan Stilgenbauer  73 , Tamar Tadmor  74 , Kristina Tomic  53 , Eric Tse  75 , Theodoros Vassilakopoulos  40 , Andrea Visentin  76 , Candida Vitale  77 , George Vrachiolias  43 , Vojin Vukovic  53   54 , Renata Walewska  14 , Zhenshu Xu  78 , Munci Yagci  79 , Lucrecia Yañez  80   81 , Mohamed Yassin  82 , Jana Zuchnicka  83 , David Oscier  14 , Alessandro Gozzetti  11 , Panagiotis Panagiotidis  16 , Francesc Bosch  6 , Paolo Sportoletti  28 , Blanca Espinet  63 , Gerassimos A Pangalis  21 , Viola M Popov  84 , Stephen Mulligan  68 , Maria Angelopoulou  40 , Fatih Demirkan  85 , Tomas Papajík  44 , Bella Biderman  86 , Roberta Murru  26 , Marta Coscia  77 , Constantine Tam  87 , Antonio Cuneo  65 , Gianluca Gaidano  57 , Rainer Claus  88   89 , Niki Stavroyianni  7 , Livio Trentin  76 , Darko Antic  53   54 , Lukas Smolej  70 , Olga B Kalashnikova  90   91 , Mark Catherwood  18 , Martin Spacek  69 , Sarka Pospisilova  4   5 , Michael Doubek  4   5 , Eugene Nikitin  17 , Anastasia Chatzidimitriou  1 , Paolo Ghia  2   3 , Kostas Stamatopoulos  1
Affiliations

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

Thomas Chatzikonstantinou et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Thomas Chatzikonstantinou received honoraria from AbbVie. Lydia Scarfò received honoraria from AbbVie, AstraZeneca, BeiGene, Lilly, Janssen, Octapharma. Gloria Iacoboni received honoraria and travel support from Novartis, Kite/Gilead, Bristol‐Myers Squibb, Abbvie, Autolus, Miltenyi, and AstraZeneca. Rosa Collado received support for attending meetings from Janssen‐Cilag and S.A. Sara Galimberti received honoraria support for attending meetings from AbbVie, AstraZeneca, Jazz, Novartis, and Incyte, honoraria from Roche, Celgene, Pfizer, and Janssen, and support for attending meetings from Jazz, AstraZeneca, and Roche. Romain Guieze received honoraria, consulting fees, and support for attending meetings from AbbVie, Beigene, Roche, Janssen, and AstraZeneca. Eleftheria Hatzimichael received honoraria from AbbVie, Janssen‐Cilag, AstraZeneca, and Roche. Yair Herishanu received honoraria from Janssen, AbbVie, Roche, AstraZeneca, Medion, and Lilly. José‐Ángel Hernández‐Rivas received honoraria as a consultant from Janssen, AbbVie, AstraZeneca, Lilly, and BeiGene and support for attending meetings from Janssen, AbbVie, AstraZeneca, and BeiGene. Ozren Jaksic received honoraria from Johnson and Johnson, AstraZeneca, and Lilly, honoraria from Johnson and Johnson, AbbVie, AstraZeneca, and Lilly, and support for attending meetings from Johnson and Johnson, and AbbVie. Kamel Laribi received consulting fees from AbbVie, AstraZeneca, Janssen, Beigene, Takeda, and Novartis. Maya Koren‐Michowitz received honoraria from Novartis, Pfizer, and Gad Medical LTD. and support for attending meetings from Novartis. Arnon P. Kater received advisory board fees and research money from Janssen, AbbVie, BMS, AstraZeneca, and Roche/Genentech, and support for attending meetings from Janssen and AbbVie. Ioannis Kotsianidis received honoraria and consulting fees from AbbVie and Janssen. Ivana Milosevic received honoraria from AbbVie, Roche, Sandoz, AstraZeneca, and Janssen, and support for attending meetings from AbbVie, Roche, and Takeda. Almudena Navarro‐Bailón received honoraria, advisory board fees, and support for attending meetings from AbbVie, AstraZeneca, Takeda, Janssen, and Beigene. Jacopo Olivieri received honoraria from AbbVie, AstraZeneca, and Janssen. Gianluigi Reda received consulting fees from AbbVie, AstraZeneca, Janssen, and Beigene, and is currently employed by AstraZeneca. Gian M. Rigolin received honoraria for participation in speaker's bureau from AbbVie, Astra Zeneca, Beigene, and Janssen, and support for attending meetings from Janssen. Mattia Schipani received honoraria and support for attending meetings from AstraZeneca, AbbVie, and Janssen‐Cilag and owns shares of stock in AbbVie, AstraZeneca, Merck, Eli Lilly, Sanofi, Johnson and Johnson, Pfizer, Gilead, and GSK. Tereza Shokralla and Stephan Stilgenbauer reports research funding from, consultancy or advisory role for, honoraria from, speakers' bureau participation for, and travel support from AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann‐La Roche, Incyte, Infinity, Janssen, Novartis, and Sunesis. Eric Tse received support for attending meetings from Takeda. Theodoros Vassilakopoulos received honoraria from Takeda, Roche, Genesis Pharma, Merck, Novartis, Gilead, Sandoz, AstraZeneca, Integris, and Servier, and support for attending meetings from Takeda, Roche, Genesis Pharma, Merck, Pfizer, and Winmedica. Candida Vitale received honoraria from AbbVie, consulting fees from AstraZeneca, and support for attending meetings from AstraZeneca, Takeda, and Janssen. Renata Walewska received honoraria from AbbVie, AstraZeneca, and Beigene, support for attending meetings from Janssen, AbbVie, and AstraZeneca, and advisory board fees from AbbVie, AstraZeneca, Janssen, Beigene, and SecuraBio. Lucrecia Yañez received honoraria from AbbVie, AstraZeneca, Novartis, Gilead, Janssen, Jazz, MSD, and Pfizer, support for attending meetings from AbbVie, AstraZeneca, Gilead, Janssen, and Pfizer, and advisory board fees from AbbVie, AstraZeneca, Jazz, Janssen, Beigene, and Celgene. Francesc Bosch received consulting fees, honoraria, and payment for expert testimony from AbbVie, Genentech, Novartis, Takeda, Janssen, Roche, Mundipharma, Celgene/BMS, AstraZeneca, Lilly, Beigene, Gilead and TG Therapeutics, Advantage Allogene, Lava Therapeutics, and Enterome. Stephen Mulligan received advisory board fees from AbbVie, AstraZeneca, Janssen, Roche, and BeiGene. Maria Angelopoulou received consulting fees from AbbVie, Takeda, Janssen, Roche, Genesis, Gilead, and Amgen and honoraria from AbbVie, Takeda, Roche, Genesis, Gilead, and Novartis. Fatih Demirkan received support for attending meetings from Janssen and AbbVie. Tomas Papajík received honoraria and advisory board fees from AbbVie, Janssen‐Cilag, and AstraZeneca, and support for attending meetings from AstraZeneca. Marta Coscia received honoraria, advisory board fees, and support for attending meetings from AbbVie, AstraZeneca, and Janssen. Constantine Tam received honoraria from AbbVie, Beigene, Janssen, and LOXO. Antonio Cuneo received honoraria, advisory board fees, and support for attending meetings from AbbVie, AstraZeneca, Beigene, Janssen, and Lilly. Gianluca Gaidano received honoraria from Abbvie, AstraZeneca, BeiGene, Hikma, Incyte, Janssen, and Lilly. Niki Stavroyianni received honoraria from Janssen, AbbVie, AstraZeneca, and Lilly, and support for attending meetings from Janssen and AstraZeneca. Lukas Smolej received consulting fees, honoraria, and support for attending meetings from AbbVie, AstraZeneca, and Janssen and advisory board fees from AbbVie and AstraZeneca. Martin Spacek received honoraria and consulting and advisory board fees, and support for attending meetings from AbbVie, AstraZeneca, and Janssen. Michael Doubek received research support and honoraria from AbbVie, AstraZeneca, and Janssen. Eugene Nikitin received honoraria from AbbVie. Kostas Stamatopoulos received research support from AbbVie, AstraZeneca, Janssen, Novartis, and Roche; honoraria from AbbVie, AstraZeneca, Bristol Myers Squibb, Lilly, and Janssen. Paolo Ghia received research support from AbbVie, AstraZeneca, BMS, Janssen and honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Galapagos, Genmab, Janssen, Loxo Oncology @Lilly, MSD, Roche, and is an Editor of HemaSphere. Georgios Karakatsoulis, Eva Minga, Dimitra Chamou, Jana Kotaskova, Christos Demosthenous, Elisa Albi, Miguel Alcoceba, Salem Al‐Shemari, Thérèse Aurran‐Schleinitz, Francesca Bacchiarri, Sofia Chatzileontiadou, Zadie Davis, Marcos Daniel de Deus Santos, Maria Dimou, Elena Dmitrieva, David Donaldson, Gimena Dos Santos, Barbara Dreta, Maria Efstathopoulou, Shaimaa El‐Ashwah, Alicia Enrico, Andrzej Frygier, Andrea Galitzia, Eva Gimeno, Valerio Guarente, Sean Harrop, Elżbieta Kalicińska, Volkan Karakus, Bonnie Kho, Maria Kislova, Εliana Konstantinou, Zuzana Kubova, Jorge Labrador, Deepesh Lad, Luca Laurenti, Thomas Longval, Alberto Lopez‐Garcia, Juan Marquet, Stanislava Maslejova, Carlota Mayor‐Bastida, Biljana Mihaljevic, Fatima Miras, Riccardo Moia, Marta Morawska, Uttam K. Nath, Irina Panovska‐Stavridis, Maria Papaioannou, Cheyenne Pierie, Anna Puiggros, Rosa Ruchlemer, Annett Schiwitza, Yandong Shen, Tereza Shokralla, Martin Simkovic, Svetlana Smirnova, Dina S. A. Soliman, Tamar Tadmor, Kristina Tomic, Andrea Visentin, George Vrachiolias, Vojin Vukovic, Zhenshu Xu, Munci Yagci, Mohamed Yassin, Jana Zuchnicka, David Oscier, Alessandro Gozzetti, Panagiotis Panagiotidis, Blanca Espinet, Paolo Sportoletti, Gerassimos A. Pangalis, Viola M. Popov, Bella Biderman, Roberta Murru, Rainer Claus, Livio Trentin, Darko Antic, Olga B. Kalashnikova, Mark Catherwood, Sarka Pospisilova, and Anastasia Chatzidimitriou have no conflict of interest to disclose.

Figures

Figure 1
Figure 1
Sunburst diagram of treatment patterns. Each color represents a distinct regimen, and each layer represents a new treatment line starting from the first line (inner‐most layer) to the third line (outer layer). The “not received” groups include patients who did not receive a new treatment line either due to continued response to the prior treatment or death.
Figure 2
Figure 2
Barplots representing the percentage of patients treated with different regimens. (A) In second line, before and after 2014, (B) in third line, before and after 2014, (C) in fourth and subsequent lines, before and after 2014, (D) in second line, including only patients with an early (<24 months) need for second line treatment after 2016.
See this image and copyright information in PMC

References

    1. Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329:918‐932. - PubMed
    1. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib‐treated patients in the United States: a real‐world analysis. Haematologica. 2018;103:874‐879. - PMC - PubMed
    1. Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353‐1363. - PMC - PubMed
    1. Ghia P, Pluta A, Wach M, et al. Ascend: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849‐2861. - PubMed
    1. Mattsson A, Sylvan SE, Axelsson P, et al. Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: a Swedish nation‐wide real‐world report on consecutively identified patients. Eur J Haematol. 2023;111:715‐721. - PubMed

LinkOut - more resources